thelancet.com
Safety, recovery, and pharmacodynamics of CRISPR–Cas therapeutic SNIPR001: a phase 1, randomised, double-blind, first-in-human, dose-escalation study
This first-in-human study of SNIPR001 supported its safety, tolerability, and restriction
to the gastrointestinal tract, while not systemically disrupting the gut microbiome.
These results justify fur...